Juniper Pharmaceuticals Inc (NASDAQ:JNP) was the target of a large drop in short interest in April. As of April 13th, there was short interest totalling 132,588 shares, a drop of 18.7% from the March 31st total of 163,022 shares. Based on an average trading volume of 37,083 shares, the short-interest ratio is currently 3.6 days.
Shares of Juniper Pharmaceuticals (NASDAQ:JNP) opened at 4.05 on Friday. The stock has a market cap of $43.91 million, a price-to-earnings ratio of 7.17 and a beta of 0.25. The company has a 50-day moving average price of $4.26 and a 200 day moving average price of $4.98. Juniper Pharmaceuticals has a one year low of $3.65 and a one year high of $8.00.
Juniper Pharmaceuticals (NASDAQ:JNP) last announced its quarterly earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.04. Juniper Pharmaceuticals had a negative net margin of 7.44% and a negative return on equity of 9.68%. The business had revenue of $11.25 million during the quarter, compared to analysts’ expectations of $11.27 million. Equities research analysts expect that Juniper Pharmaceuticals will post ($0.45) earnings per share for the current year.
Several brokerages have recently issued reports on JNP. Roth Capital set a $12.00 target price on Juniper Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, May 6th. HC Wainwright reaffirmed a “hold” rating on shares of Juniper Pharmaceuticals in a research report on Monday, May 15th. Finally, TheStreet raised Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Wednesday, April 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $9.17.
Several institutional investors have recently made changes to their positions in JNP. Vanguard Group Inc. raised its position in shares of Juniper Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 451,338 shares of the specialty pharmaceutical company’s stock valued at $2,144,000 after buying an additional 1,942 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Juniper Pharmaceuticals by 21.7% in the first quarter. Renaissance Technologies LLC now owns 309,500 shares of the specialty pharmaceutical company’s stock valued at $1,470,000 after buying an additional 55,200 shares in the last quarter. Stonepine Capital Management LLC raised its position in shares of Juniper Pharmaceuticals by 31.3% in the fourth quarter. Stonepine Capital Management LLC now owns 228,392 shares of the specialty pharmaceutical company’s stock valued at $1,279,000 after buying an additional 54,425 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Juniper Pharmaceuticals by 26.3% in the third quarter. Wells Fargo & Company MN now owns 145,586 shares of the specialty pharmaceutical company’s stock valued at $808,000 after buying an additional 30,286 shares in the last quarter. Finally, Algert Global LLC raised its position in shares of Juniper Pharmaceuticals by 28.9% in the first quarter. Algert Global LLC now owns 108,315 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 24,270 shares in the last quarter. Hedge funds and other institutional investors own 33.12% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/05/20/juniper-pharmaceuticals-inc-jnp-short-interest-down-18-7-in-april-updated-updated.html.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc, formerly Columbia Laboratories, Inc, is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE.
Receive News & Ratings for Juniper Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.